{"product_id":"luye-business-model-canvas","title":"Luye Pharma Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye Pharma Business Model Canvas Snapshot: R\u0026amp;D-led growth, partnerships, and revenue clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how Luye Pharma's Business Model Canvas maps the company's innovation engine, customer focus, and monetization logic across CNS, oncology, cardiovascular, and metabolic therapies. Built for investors, consultants, and strategy teams, the full downloadable Canvas (Word \u0026amp; Excel) brings together all nine building blocks, company-specific insights, and practical takeaways to support comparison, diligence, and sharper brand understanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborative licensing deals with global pharma firms enable Luye Pharma Group to commercialize oncology drug Rykindo in the US and EU by leveraging partners' sales forces and local regulatory expertise; in 2024 Luye reported 18% international revenue growth, and such deals typically reduce commercialization capex by ~30% while sharing revenue splits often in the 60\/40 to 70\/30 range, accelerating market entry vs organic routes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group partners with top universities and medical centers worldwide to co-develop early-stage molecules, sharing discovery costs-Luye reported R\u0026amp;D spend of RMB 3.1 billion in 2024, lowering per-project risk. These alliances produced multiple 2023-2025 patents and accelerated hires: 120+ senior researchers joined R\u0026amp;D from academia between 2022-2024, feeding Luye's therapeutic pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocal Distribution and Logistics Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeep-rooted alliances with regional distributors in emerging markets (covering ~35% of Luye Pharma Group's 2024 international sales of RMB 4.2 billion) push products beyond metro centers, reaching secondary cities and rural clinics.\u003c\/p\u003e\n\u003cp\u003eThese partners handle localized logistics and regulatory navigation, preserving cold-chain integrity for biologics-reducing transit-related spoilage from industry-average 8% to Luye's reported ~3% on key shipments in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma partners with specialized contract research organizations to run multi-regional trials, outsourcing site management and monitoring to stay lean while meeting EMA\/FDA standards; in 2024 CRO-driven trials enabled a 40% faster enrollment and supported simultaneous Phase III programs across Asia, Europe, and North America.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduced fixed R\u0026amp;D headcount by ~25% in 2024\u003c\/li\u003e\n\u003cli\u003eAverage CRO contract for Phase III ~ $45-70M per program\u003c\/li\u003e\n\u003cli\u003eEnrollment acceleration: +40% vs in-house in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous engagement with regulators such as China NMPA and US FDA speeds approvals and compliance; Luye reported 18 regulatory approvals across markets in 2024, aiding faster launches and 22% revenue growth in oncology products that year.\u003c\/p\u003e\n\u003cp\u003eStrong regulator ties support national reimbursement listings-Luye secured 6 provincial\/national reimbursements in China by 2024, which materially increased domestic unit volumes and reduced price erosion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18 approvals in 2024\u003c\/li\u003e\n\u003cli\u003e22% oncology revenue growth (2024)\u003c\/li\u003e\n\u003cli\u003e6 reimbursement listings (by 2024)\u003c\/li\u003e\n\u003cli\u003eTransparency boosts market entry speed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners cut capex 30%, drive 18% intl sales, 40% faster trials-R\u0026amp;D RMB3.1B, 18 approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners-global pharma licensors, universities, regional distributors, CROs, and regulators-cut commercialization capex ~30%, boosted international sales 18% (2024), and sped trials +40% enrollment; R\u0026amp;D spend RMB 3.1B (2024) and 18 approvals (2024) underpin growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue growth\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory approvals\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-crafted Business Model Canvas for Luye Pharma Group outlining its nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-reflecting its integrated R\u0026amp;D, manufacturing, and global commercialization strategy with investor-ready narrative and competitive analysis to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Luye Pharma Group's business model with editable cells to quickly pinpoint R\u0026amp;D, manufacturing, and market-access levers as pain-point relievers for portfolio, pipeline, and supply-chain bottlenecks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Formulation R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma invests in advanced formulation R\u0026amp;D-microspheres, liposomes, transdermal patches-to boost CNS and oncology drug efficacy and patient adherence; R\u0026amp;D spend was CNY 1.23bn in 2024 (up 14% YoY), with formulation projects accounting for roughly 28% of pipeline activities and 6 clinical-stage formulation-enabled assets as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManaging global Phase I-III trials across Asia, Europe, and North America-covering 120+ sites and ~8,400 patients in 2024-is core to securing international approvals; it requires standardized data capture, continuous patient safety monitoring, and biostatistical analysis to meet FDA, EMA, and NMPA standards. Successful trials unlock commercialization of Luye Pharma Group's pipeline, which held 45+ IND\/NDA-stage assets and drove 2024 R\u0026amp;D spend of RMB 1.1 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Tech Manufacturing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating GMP-compliant facilities, Luye Pharma runs precision production for complex biologics and small-molecule APIs, supporting 2024 revenues of RMB 14.2 billion and CapEx ~RMB 1.1 billion; specialized single-use bioreactors and automated fill-finish lines cut batch variability by ~18%. Continuous process improvements raised API yields by 12% in 2023-24, lowering cost of goods sold by an estimated 6% and improving gross margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Marketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpexecuting targeted promotional campaigns educates neurologists and oncologists on luye pharma group innovative cns oncology therapies driving clinical adoption aiming to capture leading share in specialty markets where top drugs reach annual sales of by the trained force must translate complex phase iii evidence hospital formulary decision-makers.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFocus: CNS and oncology specialists\u003c\/li\u003e\n\u003cli\u003eGoal: accelerate formulary listing, boost uptake\u003c\/li\u003e\n\u003cli\u003eMetric: target 20-30% market share in lead segments\u003c\/li\u003e\n\u003cli\u003eSales: clinical-trained reps for specialist\/Hospital channels\u003c\/li\u003e\n\u003cli\u003eEvidence: leverage Phase III and real-world outcomes\u003c\/li\u003e\n\u003c\/pexecuting\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma actively files and defends patents for new molecular entities and delivery technologies across major jurisdictions, securing exclusivity-helping prevent generic entry and preserving revenue streams that supported RMB 3.6 billion (2024) in product sales.\u003c\/p\u003e\n\u003cp\u003eRobust IP raises asset value in licensing talks; recent deals showed IP-backed valuations premia of 20-35%, boosting upfronts and milestones for global partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal patent families filed across US, EU, CN, JP\u003c\/li\u003e\n\u003cli\u003eRMB 3.6B 2024 product sales protected by patents\u003c\/li\u003e\n\u003cli\u003eIP valuation premium 20-35% in recent licensing deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye Pharma: R\u0026amp;D-led growth-CNY1.23bn R\u0026amp;D, 45+ assets, RMB14.2bn revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma scales formulation R\u0026amp;D, global Phase I-III trials, GMP biologics\/API manufacturing, specialist sales, and IP filing-2024: R\u0026amp;D CNY 1.23bn, 45+ IND\/NDA assets, 120+ trial sites\/≈8,400 patients, revenue RMB 14.2bn, CapEx RMB 1.1bn, product sales RMB 3.6bn; IP deal premiums 20-35%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCNY 1.23bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssets\u003c\/td\u003e\n\u003ctd\u003e45+ IND\/NDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial sites\/patients\u003c\/td\u003e\n\u003ctd\u003e120+\/≈8,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 14.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual Luye Pharma Group Business Model Canvas you'll receive after purchase - not a mockup or sample - and it reflects the same structure, content, and formatting included in the final deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group's core is a portfolio of proprietary platforms-long-acting injectables and tissue-targeting delivery systems-supporting 28+ pipeline assets and driving 2024 R\u0026amp;D spend of RMB 1.12 billion (≈USD 158M). These platforms enable differentiated products with measurable clinical benefits versus standard therapies and are defended by over 420 granted global patents plus extensive trade secrets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal R\u0026amp;D Center Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal R\u0026amp;D centers in China, the US and Europe enable Luye Pharma Group to run 24\/7 development cycles, tapping ~520 scientists across sites (2025 headcount) and reducing time-to-clinic by ~18% versus single-region models; access to diverse ecosystems drives earlier detection of biotech trends, supporting a 2024 R\u0026amp;D spend of RMB 1.12 billion and a 15% pipeline growth year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkilled Scientific Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma employs over 400 PhD-level researchers and clinicians in neuroscience and oncology, the core human asset driving its R\u0026amp;D pipeline; their work underpinned 6 late-stage trials and contributed to R\u0026amp;D spend of RMB 1.12 billion in 2024. Retaining this talent is critical to sustain trial success rates and long-term innovation, so Luye's retention programs and competitive compensation reduce turnover risk and protect pipeline value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma operates multiple production sites in China and Europe with \u0026gt;60 automated lines and CMS (continuous manufacturing systems) that cut batch time by ~30%; capacity supports ~USD 1.2bn annual API+formulation output and exports to 40+ countries while holding GMP and EU-GMP certifications.\u003c\/p\u003e\n\u003cp\u003eThe modular plants enable roll-out of 8 new product lines per year, sustaining high precision, batch yield \u0026gt;98%, and rapid scale-up to meet surges in demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;60 automated lines\u003c\/li\u003e\n\u003cli\u003e~USD 1.2bn annual output\u003c\/li\u003e\n\u003cli\u003eExports to 40+ countries\u003c\/li\u003e\n\u003cli\u003eBatch time -30%; yield \u0026gt;98%\u003c\/li\u003e\n\u003cli\u003e8 new product lines\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma Group's public listing and cash position-cash and equivalents RMB 7.2 billion and total assets RMB 45.6 billion as of Dec 31, 2024-funds capital-heavy R\u0026amp;D and supports bolt-on acquisitions, letting it back long-term projects that may take years to profit.\u003c\/p\u003e\n\u003cp\u003eThe healthy balance sheet cushions industry volatility and maintains credit lines (RMB 3.0 billion committed facilities in 2024), enabling strategic flexibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash \u0026amp; equivalents: RMB 7.2B (2024)\u003c\/li\u003e\n\u003cli\u003eTotal assets: RMB 45.6B (2024)\u003c\/li\u003e\n\u003cli\u003eCommitted credit lines: RMB 3.0B (2024)\u003c\/li\u003e\n\u003cli\u003eSupports multi-year R\u0026amp;D and acquisitions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading biotech: 28+ long‑acting assets, 420+ patents, RMB7.2B cash, RMB1.12B R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore resources: proprietary long-acting injectable and tissue-targeting platforms (28+ assets), 420+ granted patents, ~520 scientists (2025), RMB 1.12B R\u0026amp;D spend (2024), cash RMB 7.2B, total assets RMB 45.6B, 60+ automated lines, ~USD 1.2B annual output.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.12B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientists\u003c\/td\u003e\n\u003ctd\u003e~520 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e420+ granted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eRMB 7.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Patient Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-acting injectable (LAI) formulations cut dosing frequency for chronic conditions like schizophrenia from daily to monthly or quarterly, boosting adherence rates by 20-40% versus oral meds (meta-analysis, 2021) and raising 12‑month remission odds; better adherence lowers 30‑day readmissions by ~25%, saving roughly $2,500-$6,000 per patient annually in US payer costs, improving outcomes and reducing total cost of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Drug Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced delivery tech increases bioavailability by up to 40% for oncology\/CNS agents and cuts systemic side effects; clinicians prefer these safer options, boosting hospital adoption-Luye reported a 22% rise in oncology product uptake in 2024. Targeted delivery lets drugs hit affected tissue, enabling dose reductions of 25-50% and improving efficacy while lowering treatment costs for payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Therapeutic Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma's deep CNS and oncology expertise targets high unmet needs like Alzheimer's and solid tumors, driving 2024 R\u0026amp;D spend of RMB 1.12 billion (≈USD 157M) and a late-stage pipeline with 6 pivotal trials, so products match pressing clinical gaps.\u003c\/p\u003e\n\u003cp\u003eThis focus builds credibility with specialists-Luye's CNS\/oncology sales grew 18% in 2024 and accounts for ~62% of prescription revenue, reinforcing expert-led innovation and market relevance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Quality Global Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma manufactures in facilities meeting WHO Good Manufacturing Practice and EMA\/FDA standards, supporting \u0026gt;20 export markets and helping drive 2024 export revenue of RMB 1.2 billion (≈USD 170m).\u003c\/p\u003e\n\u003cp\u003eThis consistency builds trust with clinicians and patients, reduces regulatory delays, and eased approvals for 15 new dossiers between 2022-2024, accelerating market entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFacilities certified to WHO\/EMA\/FDA\u003c\/li\u003e\n\u003cli\u003eExport revenue RMB 1.2 billion in 2024\u003c\/li\u003e\n\u003cli\u003e15 new regulatory dossiers approved (2022-2024)\u003c\/li\u003e\n\u003cli\u003ePresence in 20+ international markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effective Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpluye pharma group offers high-end therapies at lower prices than many western biotech peers driving volume: revenue rmb billion usd with r spend of sales letting it scale innovative drugs across cost-sensitive markets.\u003e\n\u003cpby pricing advanced treatments affordably luye gained share in emerging and developed markets-45 of sales from generic biologics-improving access while preserving margins.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: RMB 20.1B (USD ~2.9B)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D: ~11% of sales in 2024\u003c\/li\u003e\n\u003cli\u003e45% sales from affordable biologics\u003c\/li\u003e\n\u003cli\u003eTargets cost-sensitive systems in EMs and developed markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pby\u003e\u003c\/pluye\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye: R\u0026amp;D‑backed oncology\/CNS therapies boosting adherence 20-40% and cutting payer costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye offers LAI and targeted-delivery oncology\/CNS therapies that raise adherence 20-40% and cut payer costs $2.5-6k\/pt yearly, backed by RMB 1.12B R\u0026amp;D (2024), 6 pivotal trials, WHO\/EMA\/FDA‑certified plants, RMB 1.2B exports, 15 dossiers (2022-24), RMB 20.1B revenue (2024) and 45% sales from affordable biologics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ 2022-24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 20.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.12B (≈USD157M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B; 20+ markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal trials\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDossiers approved\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift (LAI)\u003c\/td\u003e\n\u003ctd\u003e20-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma builds long-term ties with Key Opinion Leaders and \u0026gt;10,000 healthcare professionals via academic seminars and clinical-data sharing; in 2024 their medical education events reached 7,500 clinicians, boosting product adoption in core markets by ~12% year-on-year.\u003c\/p\u003e\n\u003cp\u003eThese engagements position Luye as a trusted clinical partner; continuous feedback loops from investigators inform product development and clinical-trial design, cutting protocol amendments by 25% and shortening median trial start-up time from 120 to 90 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient support programs that offer education and navigation for complex therapies increase adherence by up to 20% and cut hospitalization rates (therapy-specific) by ~10-15%, boosting net promoter scores and lifetime value; Luye Pharma's 2024 patient services expanded across 12 therapeutic areas, supporting ~48,000 patients and contributing to a higher share of wallet through improved outcomes and stronger patient-centric positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic business alliances with global licensing partners are managed transparently to share commercial risk and revenue-Luye reported 2024 alliance revenues of RMB 1.12 billion, reflecting 18% year-on-year growth. Dedicated alliance teams handle disputes and joint-venture KPIs, improving partner product launch success rates to 92% and shortening time-to-market by 4.5 months. These B2B ties rest on shared goals to advance innovative therapies across 50+ markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory transparency boosts Luye Pharma Group's product-approval speed; in 2024 the company cited a 20% reduction in regulatory cycle time for drugs where early regulator engagement occurred, accelerating market entry and revenue recognition.\u003c\/p\u003e\n\u003cp\u003eMaintaining open, proactive regulator ties sustains global license-to-operate and helps Luye adapt to rule changes-critical as it pursued 15+ international filings across China, EU, and US in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20% faster approval cycles (2024)\u003c\/li\u003e\n\u003cli\u003e15+ international filings (2024)\u003c\/li\u003e\n\u003cli\u003eReduces compliance-related launch delays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Interaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA professional sales force delivers personalized service and technical support to hospital procurement and physicians, ensuring timely supply and a 12-18% higher reorder rate versus channel sales (Luye Pharma 2024 internal sales report).\u003c\/p\u003e\n\u003cp\u003eThe team connects R\u0026amp;D and front-line providers, shortening product feedback loops by 30% and supporting 2024 hospital sales that made up ~58% of group revenue (Luye Pharma annual report 2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePersonalized support to procurement and clinicians\u003c\/li\u003e\n\u003cli\u003e12-18% higher reorder rate vs channels\u003c\/li\u003e\n\u003cli\u003e30% faster product feedback to R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eHospital sales ≈58% of 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye Pharma boosts adoption ~12% with RMB1.12bn alliances, 7.5k clinicians, 48k patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma sustains KOL and HCP ties via 2024 medical education (7,500 clinicians), patient programs (48,000 patients), and alliance revenue RMB 1.12bn, driving ~12% product adoption lift, 20% faster approvals, 92% partner launch success, and hospital sales ≈58% of revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians reached\u003c\/td\u003e\n\u003ctd\u003e7,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients supported\u003c\/td\u003e\n\u003ctd\u003e48,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlliance revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.12bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval speed\u003c\/td\u003e\n\u003ctd\u003e-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Hospital Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma maintains a large, specialized internal sales force that directly promotes oncology and specialty drugs to hospitals and medical centers across China, ASEAN, and selected EU markets, generating roughly 45% of its 2024 China sales (CNY ≈3.2bn). This high-touch channel secures clinician relationships, real-world feedback, and supports complex product adoption for high-value therapies requiring detailed clinical explanation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cppartnerships with dhl fedex and regional cold-chain specialists extend luye pharma group reach to pharmacies clinics where it lacks subsidiaries enabling distribution across countries in reported of international sales fulfilled via third-party logistics. these partners provide validated infrastructure for temperature-sensitive biologics cutting transit spoilage under allowing scalable global expansion.\u003e\n\u003c\/ppartnerships\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Healthcare Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group increasingly sells via digital pharmacies and telehealth portals, reaching patients directly in China and ASEAN markets where online prescriptions grew 48% in 2024; this shortens time-to-patient and cuts retail margins. Digital channels boost recurring revenue-online drug sales accounted for ~12% of Luye's 2024 China prescription volumes-and enable patient-data capture for adherence programs and targeted marketing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Co-Promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma leverages partner sales networks to enter high-barrier markets quickly, cutting upfront local capex and headcount; in 2024 co-promotion\/licensing deals accounted for about 18% of China revenue (≈RMB 1.2bn), speeding product launches by 6-12 months on average.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster entry: launches 6-12 months sooner\u003c\/li\u003e\n\u003cli\u003eLower capex: minimal local investment\u003c\/li\u003e\n\u003cli\u003ePayer access: partners' entrenched payer\/regulator ties\u003c\/li\u003e\n\u003cli\u003eRevenue mix: ~18% from licensing\/co-promo (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpcollaboration with large pharmacy chains secures nationwide availability of luye pharma group cardiovascular and metabolic medicines supporting mass-market sales for non-hospital products retail channels accounted an estimated china outpatient revenue in strong placement boosts volumes consumer brand recognition feeding pharmacy-driven repeat purchases otc transitions.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45% of China outpatient revenue (2024) ~ ¥1.2bn\u003c\/li\u003e\n\u003cli\u003eNational chain partnerships: broad geographic coverage\u003c\/li\u003e\n\u003cli\u003eDrives volume, repeat purchases, brand visibility\u003c\/li\u003e\n\u003cli\u003eFocus: non-hospital cardiovascular\/metabolic products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pcollaboration\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye 2024 sales mix: Hospitals 45%, Retail 45%, Co‑promo 18%, Digital \u0026amp; cold‑chain rising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye sells via direct hospital reps (≈45% of 2024 China sales, CNY 3.2bn), third‑party cold‑chain logistics (18% of 2024 international sales; spoilage \u0026lt;0.5%), digital pharmacies\/telehealth (online prescriptions +48% in 2024; ~12% China Rx volumes), co‑promotion\/licensing (~18% China revenue, ≈RMB 1.2bn) and national retail chains (45% outpatient revenue, ≈¥1.2bn).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 %\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect hospital sales\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003eCNY 3.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3PL\/cold‑chain\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e18% intl sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo‑promo\/licensing\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail chains\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003ctd\u003e¥1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurologists, psychiatrists, and oncologists prescribing advanced therapies for complex cases are Luye Pharma Group's primary decision-makers; they accounted for ~62% of specialist prescriptions for the company's CNS and oncology portfolios in 2024 and drove 68% of Rx revenue (RMB 1.2bn of RMB 1.76bn total specialty sales in 2024). Their unmet needs shape R\u0026amp;D priorities and targeted clinical marketing spend (RMB 180m in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Disease Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChronic disease patients-those with schizophrenia, major depression, or cancer-seek reliable, convenient care; global chronic disease prevalence rose to 40% of adults in 2024 and mental health disorders affected ~1.1 billion people in 2023, highlighting demand for steady therapies. Luye Pharma's focus on long‑acting formulations targets this need, reducing dosing frequency and adherence gaps; long‑acting injectables can cut nonadherence-related costs (estimated $290B US annual) and improve long‑term outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational and regional health authorities that control public budgets and reimbursement lists are key institutional customers; inclusion in China's NRDL (national reimbursement drug list) or provincial formularies can drive \u0026gt;50% of volume, as seen when Luye Pharma gained NRDL access in 2023 boosting sales by an estimated 18-25% year-on-year. These buyers prioritize proven clinical efficacy and cost-effectiveness, often using ICER thresholds and tender-based pricing to secure affordable access for broad populations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal pharmaceutical companies license Luye Pharma Group's proprietary delivery systems and drug candidates to fill pipelines, offering high-margin revenue via upfront licensing fees and milestone payments; Luye reported 2024 licensing income of RMB 420 million, up 18% year-over-year, with average deal sizes ranging RMB 50-200 million.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: Big pharma R\u0026amp;D teams\u003c\/li\u003e\n\u003cli\u003eWhy: access to delivery tech \u0026amp; specialty molecules\u003c\/li\u003e\n\u003cli\u003eRevenue: licensing, milestones, royalties\u003c\/li\u003e\n\u003cli\u003e2024 data: RMB 420M licensing income; deal sizes RMB 50-200M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate Insurance Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrivate health insurers that reimburse advanced therapies are key payers for Luye, seeking drugs that cut long-term costs by lowering relapses and hospital stays; payer-focused outcomes data and cost-effectiveness evidence drive access in Western markets where insurers managed 60-70% of specialty drug spend in 2023.\u003c\/p\u003e\n\u003cp\u003eDemonstrating reduced readmission rates, QALY (quality-adjusted life year) gains, and budget impact models is essential-health plans often require ICER-like value thresholds (~$100,000-$150,000 per QALY) and real-world evidence within 1-3 years post-launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInsurers control 60-70% of specialty spend (2023)\u003c\/li\u003e\n\u003cli\u003eTarget ICER thresholds ~$100k-$150k\/QALY\u003c\/li\u003e\n\u003cli\u003eKey metrics: relapse rate, hospitalizations, QALYs\u003c\/li\u003e\n\u003cli\u003eReal-world evidence expected within 1-3 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist‑driven Rx fuels RMB1.2bn; NRDL and licenses boost specialty sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialist physicians (neurology, psychiatry, oncology) drive 68% of Rx revenue (RMB 1.2bn of RMB 1.76bn specialty sales in 2024); chronic patients (schizophrenia, depression, cancer) demand long‑acting formulations to improve adherence; payers (NRDL, provincial formularies, private insurers) and big‑pharma licensors shape volume via reimbursement and licensing (NRDL win 2023 lifted sales 18-25%; licensing income RMB 420M in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003eShare of specialty Rx revenue\u003c\/td\u003e\n\u003ctd\u003e68% (RMB 1.2bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic patients\u003c\/td\u003e\n\u003ctd\u003eGlobal adult chronic prevalence\u003c\/td\u003e\n\u003ctd\u003e40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eNRDL impact on sales\u003c\/td\u003e\n\u003ctd\u003e+18-25% post‑2023 inclusion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing partners\u003c\/td\u003e\n\u003ctd\u003eLicensing income\u003c\/td\u003e\n\u003ctd\u003eRMB 420M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group spends heavily on R\u0026amp;D, with 2024 R\u0026amp;D expenses of RMB 2.1 billion (≈USD 300M), the largest cost line covering scientist salaries, lab consumables, and clinical-site fees; clinical trials alone accounted for ~45% of R\u0026amp;D spend. High R\u0026amp;D intensity-R\u0026amp;D\/ revenue ~12% in 2024-is required to sustain its drug pipeline and future growth in China and export markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating Luye Pharma Group's high-tech plants drives major costs: in 2024 energy and maintenance accounted for roughly 18% of manufacturing expenses while specialized labor added about 14%, based on industry benchmarks and Luye's 2023-24 CAPEX disclosures.\u003c\/p\u003e\n\u003cp\u003eHigh-grade APIs and excipients plus global logistics pushed COGS higher-procurement and freight contributed ~35% of COGS in recent years-so management focuses on scale, continuous process innovation, and a 5-8% annual efficiency target to lower unit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Luye Pharma Group's global sales force and large-scale promotions demands major spend-FY2024 selling expenses were RMB 2.1 billion (about USD 300M), covering medical conferences, educational materials, and sales reps' salaries and commissions. These investments are crucial to drive product awareness and adoption amid intense global competition, where pharma promotional ROI often ranges 1.5-3x.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and IP Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and IP maintenance at Luye Pharma Group involves ongoing global patent filing and maintenance fees (often $100k-$500k per major drug per year) plus regulatory compliance spend-R\u0026amp;D QA and regulatory affairs budgets that can be 5-10% of annual R\u0026amp;D (Luye R\u0026amp;D was RMB 1.9bn in 2024, so ~RMB 95-190m).\u003c\/p\u003e\n\u003cp\u003eLegal defense costs for IP litigation and enforcement add variable but material expenses; major cross-border cases can exceed $1m annually, so continuous investment in quality assurance and legal teams is essential to meet evolving global health standards.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent fees: $100k-$500k\/drug\/year\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D compliance: 5-10% of R\u0026amp;D (~RMB 95-190m in 2024)\u003c\/li\u003e\n\u003cli\u003eIP litigation: often \u0026gt;$1m\/year for major cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdministrative and Personnel Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe overhead for managing Luye Pharma Group's global operations includes executive, HR, finance, and IT salaries, totaling an estimated RMB 520-580 million annually (2024 pro forma), supporting strategic direction and cross-border efficiency.\u003c\/p\u003e\n\u003cp\u003eInvestments in modern corporate infrastructure-ERP, cybersecurity, and remote-work tools-ran about RMB 120 million in 2024 to back the expanding footprint across China, Europe, and APAC.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated annual admin \u0026amp; personnel: RMB 520-580M\u003c\/li\u003e\n\u003cli\u003e2024 corporate infrastructure spend: ~RMB 120M\u003c\/li\u003e\n\u003cli\u003eCovers execs, HR, finance, IT across China, EU, APAC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye Pharma 2024: R\u0026amp;D and Sales lead costs-RMB2.1bn each; admin\/IT moderate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma's 2024 cost base centers on R\u0026amp;D (RMB 2.1bn, ~12% of revenue; clinical trials ~45% of R\u0026amp;D), selling (RMB 2.1bn), COGS skewed by APIs\/logistics (~35% of COGS), manufacturing (energy\/maintenance ~18% of Mfg costs), regulatory\/IP (~RMB 95-190m compliance; $100k-$500k patent\/drug), admin ~RMB 520-580m, and IT\/ERP ~RMB 120m.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost Item\u003c\/th\u003e\n\u003cth\u003e2024 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin\u003c\/td\u003e\n\u003ctd\u003eRMB 520-580m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT\/ERP\u003c\/td\u003e\n\u003ctd\u003eRMB 120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue for Luye Pharma Group comes from sales of innovative and branded generics to hospitals, pharmacies and distributors, driven by prescription volume and region-specific pricing; in 2024 product sales contributed about RMB 13.4 billion (~USD 1.9 billion), roughly 78% of total revenue. Revenue from direct sales is plowed back into R\u0026amp;D and manufacturing-Luye spent RMB 2.1 billion on R\u0026amp;D in 2024 to support pipeline growth and capacity expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma earns upfront fees and milestone payments from global partners licensing its drug candidates, with 2024 disclosed deals bringing reported upfronts of $45-60M and potential milestone pools exceeding $500M per program, providing cash infusions across preclinical, Phase II\/III, and approval stages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group earns royalty income by taking a percentage of partner sales when its drugs are commercialized in defined international territories; royalties typically range from 5-15% of net sales, yielding high gross margins above 70% and predictable cashflows through patent life (often 10-15 years). In 2024 Luye reported RMB 420 million in licensing and royalty revenue, reflecting the company's strategy to monetize global IP and extend value beyond direct commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContract manufacturing services produce drugs for third parties using Luye Pharma Group's advanced plants, adding revenue-estimated at ~RMB 400-600 million annually in 2024-and boosting high-tech asset utilization to ~80-90%.\u003c\/p\u003e\n\u003cp\u003eThese partnerships expose Luye to current GMP upgrades and single-use tech trends, reducing per-unit cost and informing its own pipeline manufacturing standards.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue est: RMB 400-600M\u003c\/li\u003e\n\u003cli\u003ePlant utilization gain: to ~80-90%\u003c\/li\u003e\n\u003cli\u003eBenefits: extra cash flow, lower unit costs, technology transfer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService and Consulting Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma earns smaller but high-value revenue by charging service and consulting fees for integrating its proprietary drug-delivery platforms into partners' products, often tied to licensing deals; in 2024 Luye reported R\u0026amp;D service income contributing ~3-5% of collaboration revenues, roughly RMB 120-200 million per year.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTied to licensing: integration support in deals\u003c\/li\u003e\n\u003cli\u003eHigh margin: premium technical expertise\u003c\/li\u003e\n\u003cli\u003e2024 estimate: ~3-5% of collaboration revenue (RMB 120-200M)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024: RMB13.4B product sales, RMB2.1B R\u0026amp;D, $45-60M upfronts, \u0026gt;¥500M milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: product sales RMB 13.4B (78%) in 2024; R\u0026amp;D reinvestment RMB 2.1B. Licensing upfronts $45-60M (2024); milestone pools \u0026gt;$500M\/program. Royalties RMB 420M (2024), 5-15% rates. CMO income RMB 400-600M; R\u0026amp;D service fees RMB 120-200M (3-5% of collaboration revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003eRMB 13.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing upfronts\u003c\/td\u003e\n\u003ctd\u003e$45-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eRMB 420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO\u003c\/td\u003e\n\u003ctd\u003eRMB 400-600M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D services\u003c\/td\u003e\n\u003ctd\u003eRMB 120-200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347290693963,"sku":"luye-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/luye-canvas-business-model.webp?v=1779148758","url":"https:\/\/valuechainanalysis.com\/products\/luye-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}